Advertisement

Strategies and Progress of Endocrine Therapy for Patients with Metastatic Breast Cancer

  • Hope S. RugoEmail author
  • Huiping Li
  • Xinyu Gui
Chapter
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 1026)

Abstract

Breast cancer is one of the most prevalent cancers and the leading causes of cancer mortality in women worldwide and in China. For hormone receptor-positive (HR+) breast cancer, accounting for approximately 60–80% of breast cancer, endocrine therapy (ET) is the primary treatment strategy. For patients with HR+ metastatic breast cancer (MBC), there are many endocrine-based treatment options that can improve long-term outcomes and optimize quality of life. With the emergence and availability of new and effective agents, the options for ET have expanded in the last two decades. Although hormone therapy has been a standard of care for many decades, treatment must be individualized based on tumor biology and extent of disease. For example, the patients with impending organ failure may be treated with induction chemotherapy to improve organ function, followed by ET. For the patients who develop metastatic disease while on adjuvant ET, particularly when associated with organ failure, or for those with low expression of hormone receptors or expression of HER2, chemotherapy again may be a preferred initial treatment. ET blocks estrogen-driven tumor growth through different mechanisms; however, HR+ MBC can be intrinsically resistant or may acquire resistance to the treatment. Several targeted agents have been approved to use in combination with ET to improve response and delay development of resistance.

Keywords

HR+ Breast cancer Endocrine therapy ER-expressing breast cancer 

References

  1. 1.
    Litherland S, Jackson IM (1988) Antioestrogens in the management of hormone-dependent cancer. Cancer Treat Rev 15:183–194CrossRefPubMedGoogle Scholar
  2. 2.
    Buzdar AU, Robertson JF, Eiermann W, Nabholtz JM (2002) An overview of the pharmacology and pharmacokinetics of the newer generation aromatase inhibitors anastrozole, letrozole, and exemestane. Cancer 95:2006–2016CrossRefPubMedGoogle Scholar
  3. 3.
    Li HP, Ji JF, Hou KY, Jia TZ, Zhao HM, Xiao Y, Wang MP, Wang YF (2007) Clinical study of aromatase inhibitors in advanced breast cancer. J Peking Univ Health Sci 39:193–196Google Scholar
  4. 4.
    Miller WR, Bartlett J, Brodie AMH, Brueggemeier RW, di Salle E, Lonning PE, Llombart A, Maass N, Maudelonde T, Sasano H, Goss PE (2008) Aromatase inhibitors: are there differences between steroidal and nonsteroidal aromatase inhibitors and do they matter? Oncologist 13:829–837CrossRefPubMedGoogle Scholar
  5. 5.
    Mauri D, Pavlidis N, Polyzos NP, Ioannidis JP (2006) Survival with aromatase inhibitors and inactivators versus standard hormonal therapy in advanced breast cancer: meta-analysis. J Natl Cancer Inst 98:1285–1291CrossRefPubMedGoogle Scholar
  6. 6.
    Robertson JF, Osborne CK, Howell A, Jones SE, Mauriac L, Ellis M, Kleeberg UR, Come SE, Vergote I, Gertler S, Buzdar A, Webster A, Morris C (2003) Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: a prospective combined analysis of two multicenter trials. Cancer 98:229–238CrossRefPubMedGoogle Scholar
  7. 7.
    Di Leo A, Jerusalem G, Petruzelka L, Torres R, Bondarenko IN, Khasanov R, Verhoeven D, Pedrini JL, Smirnova I, Lichinitser MR, Pendergrass K, Garnett S, Lindemann JP, Sapunar F, Martin M (2010) Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer. J Clin Oncol 28:4594–4600CrossRefPubMedGoogle Scholar
  8. 8.
    Ellis MJ, Llombart-Cussac A, Feltl D, Dewar JA, Jasiowka M, Hewson N, Rukazenkov Y, Robertson JF (2015) Fulvestrant 500 mg versus anastrozole 1 mg for the first-line treatment of advanced breast cancer: overall survival analysis from the phase II FIRST study. J Clin Oncol 33:3781–3787CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Robertson J, Bondarenko IM, Trishkina E, Dvorkin M, Panasci L, Manikhas A, Shparyk Y, Cardona-Huerta S, Cheung KL, Philco-Salas MJ, Ruiz-Borrego M, Shao Z, Noguchi S, Rowbottom J, Stuart M, Grinsted LM, Fazal M, Ellis MJ (2016) Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial. Lancet 388:2997–3005CrossRefPubMedGoogle Scholar
  10. 10.
    Boer K (2017) Fulvestrant in advanced breast cancer: evidence to date and place in therapy. Ther Adv Med Oncol 9:465–479CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Gong C, Zhao Y, Wang B, Hu X, Wang Z, Zhang J, Zhang S (2017) Efficacy and safety of everolimus in Chinese metastatic HR positive, HER2 negative breast cancer patients: a real-world retrospective study. OncotargetGoogle Scholar
  12. 12.
    Seidman AD (2016) When to combine endocrine therapy with a new agent for hormone receptor-positive metastatic breast cancer in postmenopausal women. Oncology (Williston Park) 30:224–228Google Scholar
  13. 13.
    Yardley DA, Noguchi S, Pritchard KI, Burris HR, Baselga J, Gnant M, Hortobagyi GN, Campone M, Pistilli B, Piccart M, Melichar B, Petrakova K, Arena FP, Erdkamp F, Harb WA, Feng W, Cahana A, Taran T, Lebwohl D, Rugo HS (2013) Everolimus plus exemestane in postmenopausal patients with HR(+) breast cancer: BOLERO-2 final progression-free survival analysis. Adv Ther 30:870–884CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Bachelot T, Bourgier C, Cropet C, Ray-Coquard I, Ferrero JM, Freyer G, Abadie-Lacourtoisie S, Eymard JC, Debled M, Spaeth D, Legouffe E, Allouache D, El KC, Pujade-Lauraine E (2012) Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study. J Clin Oncol 30:2718–2724CrossRefPubMedGoogle Scholar
  15. 15.
    Gampenrieder SP, Rinnerthaler G, Greil R (2017) SABCS 2016: systemic therapy for metastatic breast cancer. Memo 10:86–89CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Rugo HS, Seneviratne L, Beck JT, Glaspy JA, Peguero JA, Pluard TJ, Dhillon N, Hwang LC, Nangia C, Mayer IA, Meiller TF, Chambers MS, Sweetman RW, Sabo JR, Litton JK (2017) Prevention of everolimus-related stomatitis in women with hormone receptor-positive, HER2-negative metastatic breast cancer using dexamethasone mouthwash (SWISH): a single-arm, phase 2 trial. Lancet Oncol 18:654–662CrossRefPubMedGoogle Scholar
  17. 17.
    Shah AN, Cristofanilli M (2017) The growing role of CDK4/6 inhibitors in treating hormone receptor-positive advanced breast cancer. Curr Treat Options in Oncol 18:6CrossRefGoogle Scholar
  18. 18.
    Finn RS, Dering J, Conklin D, Kalous O, Cohen DJ, Desai AJ, Ginther C, Atefi M, Chen I, Fowst C, Los G, Slamon DJ (2009) PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro. Breast Cancer Res 11:R77CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Musgrove EA, Caldon CE, Barraclough J, Stone A, Sutherland RL (2011) Cyclin D as a therapeutic target in cancer. Nat Rev Cancer 11:558–572CrossRefPubMedGoogle Scholar
  20. 20.
    Walker AJ, Wedam S, Amiri-Kordestani L, Bloomquist E, Tang S, Sridhara R, Chen W, Palmby TR, Fourie ZJ, Fu W, Liu Q, Tilley A, Kim G, Kluetz PG, McKee AE, Pazdur R (2016) FDA approval of Palbociclib in combination with fulvestrant for the treatment of hormone receptor-positive, HER2-negative metastatic breast cancer. Clin Cancer Res 22:4968–4972CrossRefPubMedGoogle Scholar
  21. 21.
    Turner NC, Ro J, Andre F, Loi S, Verma S, Iwata H, Harbeck N, Loibl S, Huang BC, Zhang K, Giorgetti C, Randolph S, Koehler M, Cristofanilli M (2015) Palbociclib in hormone-receptor-positive advanced breast cancer. N Engl J Med 373:209–219CrossRefPubMedGoogle Scholar
  22. 22.
    Finn RS, Crown JP, Lang I, Boer K, Bondarenko IM, Kulyk SO, Ettl J, Patel R, Pinter T, Schmidt M, Shparyk Y, Thummala AR, Voytko NL, Fowst C, Huang X, Kim ST, Randolph S, Slamon DJ (2015) The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. Lancet Oncol 16:25–35CrossRefPubMedGoogle Scholar
  23. 23.
    Finn RS, Crown JP, Ettl J, Schmidt M, Bondarenko IM, Lang I, Pinter T, Boer K, Patel R, Randolph S, Kim ST, Huang X, Schnell P, Nadanaciva S, Bartlett CH, Slamon DJ (2016) Efficacy and safety of palbociclib in combination with letrozole as first-line treatment of ER-positive, HER2-negative, advanced breast cancer: expanded analyses of subgroups from the randomized pivotal trial PALOMA-1/TRIO-18. Breast Cancer Res 18:67CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Lu J (2015) Palbociclib: a first-in-class CDK4/CDK6 inhibitor for the treatment of hormone-receptor positive advanced breast cancer. J Hematol Oncol 8:98CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Cristofanilli M, Turner NC, Bondarenko I, Ro J, Im SA, Masuda N, Colleoni M, DeMichele A, Loi S, Verma S, Iwata H, Harbeck N, Zhang K, Theall KP, Jiang Y, Bartlett CH, Koehler M, Slamon D (2016) Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. Lancet Oncol 17:425–439CrossRefPubMedGoogle Scholar
  26. 26.
    Finn RS, Martin M, Rugo HS, Jones S, Im SA, Gelmon K, Harbeck N, Lipatov ON, Walshe JM, Moulder S, Gauthier E, DR L, Randolph S, Dieras V, Slamon DJ (2016) Palbociclib and letrozole in advanced breast cancer. N Engl J Med 375:1925–1936CrossRefPubMedGoogle Scholar
  27. 27.
    Hortobagyi GN, Stemmer SM, Burris HA, Yap YS, Sonke GS, Paluch-Shimon S, Campone M, Blackwell KL, Andre F, Winer EP, Janni W, Verma S, Conte P, Arteaga CL, Cameron DA, Petrakova K, Hart LL, Villanueva C, Chan A, Jakobsen E, Nusch A, Burdaeva O, Grischke EM, Alba E, Wist E, Marschner N, Favret AM, Yardley D, Bachelot T, Tseng LM, Blau S, Xuan F, Souami F, Miller M, Germa C, Hirawat S, O’Shaughnessy J (2016) Ribociclib as first-line therapy for HR-positive, advanced breast cancer. N Engl J Med 375:1738–1748CrossRefPubMedGoogle Scholar
  28. 28.
    Hortobagyi GN, Stemmer SM, Burris HA, Yap YS, Sonke GS, Paluch-Shimon S, Campone M, Petrakova K, Blackwell KL, Winer EP, Janni W, Verma S, Conte PF, Arteaga CL, Cameron DA, Xuan F, Miller MK, Germa C, Hirawat S, O’Shaughnessy J (2017) Updated results from MONALEESA-2, a phase 3 trial of first-line ribociclib + letrozole in hormone receptor-positive (HR+), HER2-negative (HER2–), advanced breast cancer (ABC). J Clin Oncol:1038Google Scholar
  29. 29.
    Dickler MN, Tolaney SM, Rugo HS, Cortes J, Dieras V, Patt D, Wildiers H, Hudis CA, O’Shaughnessy J, Zamora E, Yardley DA, Frenzel M, Koustenis A, Baselga J (2017) MONARCH 1, A phase II study of abemaciclib, a CDK4 and CDK6 inhibitor, as a single agent, in patients with refractory HR+/HER2- metastatic breast cancer. Clin Cancer Res 23(17):5218–5224CrossRefPubMedGoogle Scholar
  30. 30.
    Sledge GJ, Toi M, Neven P, Sohn J, Inoue K, Pivot X, Burdaeva O, Okera M, Masuda N, Kaufman PA, Koh H, Grischke EM, Frenzel M, Lin Y, Barriga S, Smith IC, Bourayou N, Llombart-Cussac A (2017) MONARCH 2: abemaciclib in combination with fulvestrant in women with HR+/HER2- advanced breast cancer who had progressed while receiving endocrine therapy. J Clin Oncol:O2017737585Google Scholar
  31. 31.
    Di Leo A, Toi M, Campone M et al. MONARCH 3: abemaciclib as initial therapy for patients with HR+, HER2- advanced breast cancer. In: Proceedings of the ESMO 2017Google Scholar
  32. 32.
    Murphy CE, Lansdown MR, Speirs V, Carder PJ (2003) Correspondence re: K. Heer et al., serum vascular endothelial growth factor in breast cancer: its relation with cancer type and estrogen receptor status. Clin Cancer Res 7:3491–3494. 2001. Clin Cancer Res 9:3514, 3515Google Scholar
  33. 33.
    Kumler I, Christiansen OG, Nielsen DL (2014) A systematic review of bevacizumab efficacy in breast cancer. Cancer Treat Rev 40:960–973CrossRefPubMedGoogle Scholar
  34. 34.
    Martin M, Loibl S, von Minckwitz G, Morales S, Martinez N, Guerrero A, Anton A, Aktas B, Schoenegg W, Munoz M, Garcia-Saenz JA, Gil M, Ramos M, Margeli M, Carrasco E, Liedtke C, Wachsmann G, Mehta K, De la Haba-Rodriguez JR (2015) Phase III trial evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for advanced breast cancer: the letrozole/fulvestrant and avastin (LEA) study. J Clin Oncol 33:1045–1052CrossRefPubMedGoogle Scholar
  35. 35.
    Dickler MN, Barry WT, Cirrincione CT, Ellis MJ, Moynahan ME, Innocenti F, Hurria A, Rugo HS, Lake DE, Hahn O, Schneider BP, Tripathy D, Carey LA, Winer EP, Hudis CA (2016) Phase III trial evaluating letrozole as first-line endocrine therapy with or without bevacizumab for the treatment of postmenopausal women with hormone receptor-positive advanced-stage breast cancer: CALGB 40503 (Alliance). J Clin Oncol 34:2602–2609CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Johnston S, Pippen JJ, Pivot X, Lichinitser M, Sadeghi S, Dieras V, Gomez HL, Romieu G, Manikhas A, Kennedy MJ, Press MF, Maltzman J, Florance A, O’Rourke L, Oliva C, Stein S, Pegram M (2009) Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J Clin Oncol 27:5538–5546CrossRefPubMedGoogle Scholar
  37. 37.
    Kaufman B, Mackey JR, Clemens MR, Bapsy PP, Vaid A, Wardley A, Tjulandin S, Jahn M, Lehle M, Feyereislova A, Revil C, Jones A (2009) Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study. J Clin Oncol 27:5529–5537CrossRefPubMedGoogle Scholar
  38. 38.
    Swain SM, Kim SB, Cortes J, Ro J, Semiglazov V, Campone M, Ciruelos E, Ferrero JM, Schneeweiss A, Knott A, Clark E, Ross G, Benyunes MC, Baselga J (2013) Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol 14:461–471CrossRefPubMedPubMedCentralGoogle Scholar
  39. 39.
    Baselga J, Im SA, Iwata H, Cortes J, De Laurentiis M, Jiang Z, Arteaga CL, Jonat W, Clemons M, Ito Y, Awada A, Chia S, Jagiello-Gruszfeld A, Pistilli B, Tseng LM, Hurvitz S, Masuda N, Takahashi M, Vuylsteke P, Hachemi S, Dharan B, Di Tomaso E, Urban P, Massacesi C, Campone M (2017) Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 18:904–916CrossRefPubMedGoogle Scholar
  40. 40.
    Krop IE, Mayer IA, Ganju V, Dickler M, Johnston S, Morales S, Yardley DA, Melichar B, Forero-Torres A, Lee SC, de Boer R, Petrakova K, Vallentin S, Perez EA, Piccart M, Ellis M, Winer E, Gendreau S, Derynck M, Lackner M, Levy G, Qiu J, He J, Schmid P (2016) Pictilisib for oestrogen receptor-positive, aromatase inhibitor-resistant, advanced or metastatic breast cancer (FERGI): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol 17:811–821CrossRefPubMedPubMedCentralGoogle Scholar
  41. 41.
    Sabnis GJ, Goloubeva O, Chumsri S, Nguyen N, Sukumar S, Brodie AM (2011) Functional activation of the estrogen receptor-alpha and aromatase by the HDAC inhibitor entinostat sensitizes ER-negative tumors to letrozole. Cancer Res 71:1893–1903CrossRefPubMedPubMedCentralGoogle Scholar
  42. 42.
    Yardley DA, Ismail-Khan RR, Melichar B, Lichinitser M, Munster PN, Klein PM, Cruickshank S, Miller KD, Lee MJ, Trepel JB (2013) Randomized phase II, double-blind, placebo-controlled study of exemestane with or without entinostat in postmenopausal women with locally recurrent or metastatic estrogen receptor-positive breast cancer progressing on treatment with a nonsteroidal aromatase inhibitor. J Clin Oncol 31:2128–2135CrossRefPubMedPubMedCentralGoogle Scholar
  43. 43.
    Rugo HS, Delord JP, Im SA, Ott PA, PihaPaul SA, Bedard PL, Sachdev J, Tourneau CL, Brummelen EV, Varga A, Saraf S, Pietrangelo D, Karantza V, Tan A (2016) Preliminary efficacy and safety of pembrolizumab (MK-3475) in patients with PD-L1–positive, estrogen receptor-positive (ER+)/HER2-negative advanced breast cancer enrolled in KEYNOTE-028. Cancer Res 76:S5–S7CrossRefGoogle Scholar
  44. 44.
    Hurvitz S, Martin M, Fernández Abad M, Chan D, Rostorfer R, Petru E, Barriga S, Costigan TM, Caldwell CW, Nguyen T, Press M, Slamon D (2017) Biological effects of abemaciclib in a phase 2 neoadjuvant study for postmenopausal patients with HR+, HER2- breast cancer. Cancer Res 4(suppl):S4–S6Google Scholar
  45. 45.
    Rugo HS, Rumble RB, Macrae E, Barton DL, Connolly HK, Dickler MN, Fallowfield L, Fowble B, Ingle JN, Jahanzeb M, Johnston SR, Korde LA, Khatcheressian JL, Mehta RS, Muss HB, Burstein HJ (2016) Endocrine therapy for hormone receptor-positive metastatic breast cancer: American society of clinical oncology guideline. J Clin Oncol 34:3069–3103CrossRefPubMedGoogle Scholar
  46. 46.
    Gradishar WJ, Anderson BO, Balassanian R, Blair SL, Burstein HJ, Cyr A, Elias AD, Farrar WB, Forero A, Giordano SH, Goetz M, Goldstein LJ, Hudis CA, Isakoff SJ, Marcom PK, Mayer IA, McCormick B, Moran M, Patel SA, Pierce LJ, Reed EC, Salerno KE, Schwartzberg LS, Smith KL, Smith ML, Soliman H, Somlo G, Telli M, Ward JH, Shead DA, Kumar R (2015) Breast cancer version 2.2015. J Natl Compr Cancer Netw 13:448–475CrossRefGoogle Scholar
  47. 47.
    Higgins MJ, Wolff AC (2008) Therapeutic options in the management of metastatic breast cancer. Oncology (Williston Park) 22:614–623, 623, 627–629Google Scholar
  48. 48.
    Li HP, Ma LW, Zhang SL, Jia TZ, Deng HJ, Zhang ZH, Liang L, Wang MP, Xiao Y, Cao BS, Chen S, Wang YF (2006) Observation and clinical significance of adjuvant chemotherapy-induced amenorrhea in premenopausal breast cancer patients. China Oncol 28:848–851Google Scholar
  49. 49.
    Reinert T, Barrios CH (2015) Optimal management of hormone receptor positive metastatic breast cancer in 2016. Ther Adv Med Oncol 7:304–320CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. 2017

Authors and Affiliations

  1. 1.University of California San Francisco Helen Diller Family Comprehensive Cancer CenterSan FranciscoUSA
  2. 2.Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Breast OncologyPeking University, Cancer Hospital & InstituteBeijingChina

Personalised recommendations